Navigation Links
R-Tech Ueno Completes Phase 2a Clinical Study of RK-023 to Treat Androgenetic Alopecia
Date:1/24/2011

ima, MD, PhD, provided the following comments: "RK-023 has been developed as an anti-aging or a lifestyle drug that is one of the areas on research and development in R-Tech Ueno. I am very pleased to obtain the favorable results in safety assessment and in efficacy of global photo assessment. It is estimated that the global market size of drugs for androgenetic alopecia is approximately one billion US dollars. RK-023 is an important drug of our pipelines to develop our business. For the future we will facilitate this project to obtain approval more quickly with a view to the possibility of tie-up with domestic and foreign partners. RK-023 will improve the quality of life (QOL) for androgenetic alopecia patients."

Note 1) Androgenetic alopecia, which is male-pattern alopecia, is a gradually progressive hair-thinning and alopecic disease with replacement of thick long hair by thin, short and soft hair without hair regeneration localized in the parietal to the frontal region under the effect of androgenic hormone after puberty, finally leading to atrophy in the hair follicles and reduction in the number of hair. About 12 million males are affected in Japan.

Note 2) Double-blind is a study method usually on human subjects in an attempt to eliminate subjective bias on the part of both experimental subjects and experimenters.

Note 3) Study drug without medical agent

Note 4) Phototrichogram is a noninvasive technique that analyzes hair density, hair diameter and a hair growth rate. A magnified photograph on a scalp hair cut area is analyzed.

Note 5) Anagen hair is defined as hair with a growth rate of 0.2 mm or more per day through phototrichogram. Anagen is the phase during which hair grows. Decrease of an anagen hair rate represents the progression of androgenetic alopecia.

About R-Tech Ueno, Ltd.

R-Tech Ueno is a bio venture company established in September 1989 for the purpose of R&D and marketing of drugs. Under
'/>"/>

SOURCE R-Tech Ueno, Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. R-Tech Ueno, Ltd. Completes Phase 1 Clinical Study on RK-023
2. R-Tech Ueno Completes Subject Enrollment in Phase 2 Clinical Study of 0.15% UF-021
3. R-Tech Ueno Starts Early Phase II Clinical Trial for RK-023
4. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
7. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
8. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
9. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
10. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
11. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 23, 2014 In response to urgent requests from the ... Sierra Leone , Direct Relief delivered two 10-bed ... the treatment of local health workers who contract Ebola while ... Ebola care center was constructed for foreign health care workers ... available for local Sierra Leonean health workers. With ...
(Date:12/22/2014)... N.J. , Dec. 22, 2014  CytoSorbents ... marketing its CytoSorb® blood purification technology to help ... patients in 28 countries worldwide, today announced the ... , MD, FACS, as its Senior Vice President ... Dr. Di Russo is ...
(Date:12/22/2014)... 22, 2014 Research and Markets ( ... "US Self-monitoring Blood Glucose Market" report to their ... This market insight focuses on the developments in ... United States . Reimbursement analysis and the effects ... for more than 73 SMBG meters have been performed, ...
Breaking Medicine Technology:First Ebola Treatment Unit for Local Health Workers Arrives in Sierra Leone 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5US Self-monitoring Blood Glucose Market 2
... Aug. 3 Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) ... Tuesday, August 10, 2010 at 8:00 a.m. Eastern Time ( 5:00 ... Interested parties may access ... , , ...
... , CLEVELAND , Aug. 3 Researchers ... Washington University School of Medicine in St. Louis, ... use of advanced treatments for cancer patients, will soon become ... system from ViewRay™, Inc. The ViewRay system is designed to ...
Cached Medicine Technology:Onyx Pharmaceuticals to Present at the Canaccord Genuity 30th Annual Growth Conference 2Siteman Cancer Center at Barnes-Jewish and Washington University to Receive First ViewRay Radiation Therapy System 2Siteman Cancer Center at Barnes-Jewish and Washington University to Receive First ViewRay Radiation Therapy System 3
(Date:12/25/2014)... 25, 2014 Product liability lawsuits filed ... recall ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move forward in ... Order issued in the U.S. District Court, Northern District ... an open conference on January 7, 2015, at the ... in West Palm Beach, Florida. The Conference is scheduled ...
(Date:12/25/2014)... December 26, 2014 Recently, Dylan Queen, ... has excitedly released its collection of discounted prom dresses, ... Percy, a senior spokesman of the company, the promotion ... this promotion is to expand the UK market. , ... several different colors, lengths, and styles: A-line strapless, empire ...
(Date:12/25/2014)... 2014 BambooFlooringChina.com sells many bamboo products ... flooring. Today, the company announces big discounts on ... and colors. , BambooFlooringChina.com is the world’s leader in ... is valid until Jan. 20, 2015. , The bamboo ... with a natural thread. All the bamboo strips for ...
(Date:12/25/2014)... updated its blog to provide professional shopping tips on wedding and ... LunaDress.co.uk come with big discounts, up to 80 percent off. , ... to be a most exciting memory and can show off a ... a wedding. On the updated fashion blog, ladies can now find ... day . , Going out with friends to a party is ...
(Date:12/25/2014)... THURSDAY, Dec. 25, 2014 (HealthDay News) -- Overeating is common ... you eat in moderation, an expert says. "Don,t arrive ... up calories if you know you,ll be attending a party, ... Jill Ashbey-Pejoves, lead dietitian at Northern Westchester Hospital in Mount ... better to eat healthy during the day and even to ...
Breaking Medicine News(10 mins):Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2
... of $39.2 MillionCARLSBAD, Calif., April 30 Genoptix, Inc. ... provider, today reported revenues of $39.2 million for the ... benefit from changes in accounting estimates relating to prior ... over revenues of $22.3 million for the comparable period ...
... risks, agency says, , , THURSDAY, April 30 (HealthDay News) ... injections such as Botox to treat muscle spasms have ... products will now be required to carry boxed warnings, ... Food and Drug Administration announced Thursday. , Most cases ...
... HealthSouth Corporation (NYSE: HLS ) today announced ... Stock Conference on May 12-14, 2009, at the Four Seasons ... and Executive Vice President and Chief Financial Officer John Workman ... ET (7:55 a.m. CT). The presentation will be webcast live ...
... The Missouri House today amended HB21 to allocate at ... grants for maternity homes and pregnancy resource centers in the ... Missouri Senate. , , Americans United for Life ... centers are essential to helping pregnant women in need. ...
... Prospero Group (PRPG) invested into the Private ... split. Prospero Group a leading company in the field ... the new ACTRx Malaria and Dengue fever treatment. Fincor ... Prospero Group enlarges its technology portfolio with ...
... can have significant physical and psychological repercussions that impact ... it can affect their ability to remain employed. Compared ... disabilities, arthritis appears to have a more profound effect ... found that about half of those with severe forms ...
Cached Medicine News:Health News:Genoptix Reports Strong Growth for the First Quarter of 2009 2Health News:Genoptix Reports Strong Growth for the First Quarter of 2009 3Health News:Genoptix Reports Strong Growth for the First Quarter of 2009 4Health News:Genoptix Reports Strong Growth for the First Quarter of 2009 5Health News:Genoptix Reports Strong Growth for the First Quarter of 2009 6Health News:Genoptix Reports Strong Growth for the First Quarter of 2009 7Health News:Genoptix Reports Strong Growth for the First Quarter of 2009 8Health News:Genoptix Reports Strong Growth for the First Quarter of 2009 9Health News:FDA Mandates New Warnings for Botox 2Health News:FDA Mandates New Warnings for Botox 3Health News:Prospero Group (PRPG) and Fincor (FINC) Made a Share Transfer and Enter the Market with ACTRx a New Malaria and Dengue Fever Treatment 2Health News:Women with arthritis more likely than men to stop working 2Health News:Women with arthritis more likely than men to stop working 3
... Prostate specific antigen (PSA) is a serine ... within the epithelial cells of the acini and ... serum is 0.1-2.6 ng/mL. Reports have suggested that ... is the must useful tumor markers in diagnosis ...
The IDS Gamma-B 25-Hydroxy Vitamin D kit is a conventional liquid phase radioimmunoassay intended for the quantitative determination of 25-hydroxy vitamin D (25-OHD) and other hydroxylated metabolite...
A complete workstation for haemostasis , A compact and convenient analyser , A comprehensive system , An exellent reliability: the STAGO patented detection mode...
... Lancets are designed with Shallow Point Comfort ... gauge needle with its shallow-angled edges act ... penetration without tearing the skin. The unique ... to grip, even for patients with arthritis ...
Medicine Products: